Breaking News Instant updates and real-time market news.

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51

Gene therapy may be nearing 'major breakthrough,' Baron's says

Gene therapy is rapidly emerging as one of the most exciting areas in biotechnology, and generating new hope for patients with rare and often deadly inherited diseases, Andre Bary writes in this week's edition of Barron's. The first regulatory approval for replacement gene therapy could come as soon as January, if the FDA gives the go-ahead to Spark Therapeutics (ONCE) for its one-time treatment that targets a rare, inherited retinal condition leading to blindness, he adds. Other publicly traded companies developing treatments in this area include AveXis' (AVXS), Regenxbio (RGNX), Audentes Therapeutics (BOLD), and Voyager Therapeutics (VYGR).Reference Link

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

ONCE Spark Therapeutics
$85.15

-1.95 (-2.24%)

09/21/17
JEFF
09/21/17
NO CHANGE
Target $95
JEFF
Buy
Jefferies sees Spark rallying 5%-7% on positive FDA panel
Jefferies analyst Michael Yee sees a "high likelihood" for a positive FDA panel on October 12 for Spark Therapeutics' SPK-RPE65, setting up approval for the first gene therapy drug for rare blindness on or before the FDA action date of January 12, 2018. The analyst sees 5%-7% share upside on a positive vote, mostly as a "de-risking event and also a positive read-through derivative to gene therapy companies as FDA starts to approve gene therapy drugs." He keeps a Buy rating on Spark with a $95 price target.
09/14/17
RBCM
09/14/17
INITIATION
Target $100
RBCM
Outperform
Spark Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Matthew Eckler started Spark Therapeutics with an Outperform rating and $100 price target. The analyst sees the expected upcoming approval of Luxturna as having "broad positive read-through" to the company's platform. He's a buyer ahead of next month's FDA panel.
09/06/17
LEHM
09/06/17
INITIATION
Target $104
LEHM
Overweight
Spark named top pick in U.S. SMid-Cap Biotechnology at Barclays
Barclays analyst Gena Wang after the close initiated coverage of the U.S. Small & Mid Cap Biotechnology industry with a Positive view. Her top industry pick is Spark Therapeutics (ONCE). The analyst sees de-risking clinical data for several novel therapies in the biotech sector, namely from Spark, BioMarin (BMRN), AveXis (AVXS), Alnylam (ALNY) and Puma Biotechnology (PBYI). Wang believes Spark's Luxturna in RPE-65-mediated inherited retinal dystrophies could be disruptive to current treatment paradigms.
09/06/17
LEHM
09/06/17
INITIATION
Target $104
LEHM
Overweight
Spark Therapeutics initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Spark Therapeutics with an Overweight rating and $104 price target. The analyst views the company's Luxturna as a potential disruptive treatment in inherited retinal dystrophies.
AVXS AveXis
$92.11

-4.03 (-4.19%)

09/14/17
RBCM
09/14/17
INITIATION
Target $92
RBCM
Sector Perform
AveXis initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started AveXis with a Sector Perform rating and $92 price target.
09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
AveXis initiated with an Overweight at Barclays
Barclays initiated AveXis with an Overweight rating and $124 price target, citing AVXS-101 showing "impressive" clinical benefit in Ph1/2 study, which could result in it becoming a strong competitor to Spinraza.
08/29/17
08/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Esperion (ESPR) initiated with an Outperform at Northland. 2. Carter's (CRI) initiated with an Outperform at Macquarie. 3. DarioHealth (DRIO) initiated with a Buy at Aegis. 4. Helen of Troy (HELE) initiated with an Underperform at BofA/Merrill. 5. AveXis (AVXS) initiated with a Reduce at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RGNX Regenxbio
$28.25

-1.15 (-3.91%)

08/16/17
EVER
08/16/17
INITIATION
Target $25
EVER
Outperform
Regenxbio initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Regenxbio with an Outperform and a $25 price target.
09/05/17
CHDN
09/05/17
NO CHANGE
Target $75
CHDN
Buy
Regenxbio price target raised to $75 from $55 at Chardan
09/19/17
SBSH
09/19/17
DOWNGRADE
Target $5.5
SBSH
Sell
Dimension Therapeutics downgraded to Sell from Neutral at Citi
Citi analyst Joel Beatty downgraded Dimension Therapeutics (DMTX) to Sell saying his base case is now the takeover proposed by Ultragenyx (RARE) will go ahead. Since Dimension s currently trading at a small premium to the $5.50 per share proposal, the analyst downgraded the stock to Sell. Beatty sees a "small but real potential" for a higher bid to come in. He believes, however, that a successful bid from Regenxbio (RGNX) would likely need to be double its original offer. The analyst raised his price target for Dimension shares to $5.50 from $3.41.
09/19/17
BARD
09/19/17
NO CHANGE
BARD
Outperform
Ultragenyx deal for Dimension would be good strategic fit, says Baird
Baird analyst Michael Ulz noted Ultragenyx (RARE) topped Regenxbio's (RGNX) bid for Dimension Therapeutics (DMTX) with a $5.50 per share offer of its own. He views the proposed acquisition of Dimension as a good strategic fit that would add a gene therapy platform and expand the early-stage pipeline. Ulz keeps an Outperform rating on Ultragenyx shares.
BOLD Audentes Therapeutics
$27.31

-0.1 (-0.36%)

10/10/16
PIPR
10/10/16
NO CHANGE
Target $24
PIPR
Overweight
AveXis data bodes well for Audentes gene therapy program, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said additional data presented by AveXis (AVXS) from its ongoing Phase 1/2 trial in infantile-onset spinal muscular atrophy "augurs well" for Audentes Therapeutics' (BOLD) gene therapy program for X-linked myotubular myopathy, as he sees several points of similarity that provide a positive read-through though the companies are targeting different diseases. Schimmer, who does not have a rating on AveXis, reiterates his Overweight rating and $24 price target on Audentes shares.
05/01/17
LEER
05/01/17
INITIATION
Target $22
LEER
Outperform
Audentes Therapeutics initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started Audentes Therapeutics with an Outperform rating and $22 price target as he believes catalysts over the next 12 months have the potential to generate enthusiasm for the company's approach, which appears de-risked by strong preclinical animal model data.
08/16/17
EVER
08/16/17
INITIATION
Target $23
EVER
Outperform
Audentes Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Audentes Therapeutics with an Outperform and a $23 price target.
VYGR Voyager Therapeutics
$17.50

-0.22 (-1.24%)

03/01/17
NOMU
03/01/17
INITIATION
Target $31
NOMU
Buy
Voyager Therapeutics initiated with a Buy at Nomura
Nomura initiated Voyager Therapeutics with a Buy and a $31 price target.
03/31/17
STFL
03/31/17
NO CHANGE
STFL
Voyager Therapeutics has reached attractive entry point, says Stifel
After meeting with Voyager's CEO, Stifel analyst Katherine Breedis says that the company "continues to make solid progress" with its top drug, VY-AADC01. The analyst notes that the company is slated to report Phase 1B six month data for the drug in the middle of this year, and she says that it could be an important positive turning point for the shares. The analyst adds that the data may have been "de-risked" by recent improved outcomes reported by the company. Breedis thinks that VY-AADC01 has several key potential positive catalysts over the next 6-9 months,. She thinks that the stock has reached an attractive entry point and keeps a $33 price target and a Buy rating on the stock.
07/28/17
STFL
07/28/17
INITIATION
STFL
Buy
Voyager Therapeutics coverage resumed with a Buy at Stifel
Stifel analyst Thmas Shrader resumed coverage of Voyager with a $20 price target and a Buy rating. He thinks that the company's lead drug, a treatment for Parkinson's "has great promise."
08/16/17
EVER
08/16/17
INITIATION
Target $21
EVER
Outperform
Voyager Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Voyager Therapeutics with an Outperform and a $21 price target.

TODAY'S FREE FLY STORIES

STLD

Steel Dynamics

$37.78

1.34 (3.68%)

21:35
10/19/17
10/19
21:35
10/19/17
21:35
Upgrade
Steel Dynamics rating change at KeyBanc »

Steel Dynamics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

RXDX

Ignyta

$16.65

0.4 (2.46%)

20:30
10/19/17
10/19
20:30
10/19/17
20:30
Syndicate
Ignyta 10M share Secondary priced at $16.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 20

    Oct

PG

Procter & Gamble

$91.59

-0.4904 (-0.53%)

, GE

General Electric

$23.58

0.46 (1.99%)

20:25
10/19/17
10/19
20:25
10/19/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$91.59

-0.4904 (-0.53%)

GE

General Electric

$23.58

0.46 (1.99%)

HON

Honeywell

$143.62

0.18 (0.13%)

SLB

Schlumberger

$64.50

-1.41 (-2.14%)

STI

SunTrust

$59.11

-0.18 (-0.30%)

SYF

Synchrony

$31.71

0.2 (0.63%)

CFG

Citizens Financial

$37.43

0.25 (0.67%)

KSU

Kansas City Southern

$103.78

0.97 (0.94%)

GNTX

Gentex

$20.66

0.2 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 02

    Nov

WILC

G. Willi-Food

$5.85

-0.14 (-2.34%)

18:35
10/19/17
10/19
18:35
10/19/17
18:35
Hot Stocks
G. Willi-Food receives notice from Arla Food ending distribution agreement »

G. Willi-Food's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$71.26

-0.46 (-0.64%)

18:30
10/19/17
10/19
18:30
10/19/17
18:30
Hot Stocks
Macquarie Infrastructure CEO to become CEO of Macquarie Atlas Roads in 2018 »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

BIDU

Baidu

$264.52

-4.45 (-1.65%)

18:30
10/19/17
10/19
18:30
10/19/17
18:30
Hot Stocks
Baidu collaborating with China's BAIC Group and King Long for autonomous driving »

Baidu signed strategic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

IBKC

Iberiabank

$80.15

0.05 (0.06%)

18:27
10/19/17
10/19
18:27
10/19/17
18:27
Hot Stocks
IBERIABANK to acquire Gibraltar Private Bank & Trust »

IBERIABANK Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 15

    Nov

  • 28

    Nov

VBTX

Veritex

$27.04

-0.02 (-0.07%)

18:20
10/19/17
10/19
18:20
10/19/17
18:20
Hot Stocks
Veritex receives regulatory approval for Liberty Bancshares merger »

Veritex Holdings, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BHP

BHP Billiton

$41.56

0.06 (0.14%)

18:03
10/19/17
10/19
18:03
10/19/17
18:03
Hot Stocks
BHP Billiton CEO sees challenges around geopolitical uncertainty remaining »

In annual shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRRX

Durect

$1.97

0.03 (1.55%)

17:59
10/19/17
10/19
17:59
10/19/17
17:59
Hot Stocks
Durect: Phase 3 clinical trial for POSIMIR did not meet primary endpoint »

Durect reported that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTNP

Titan Pharmaceuticals

$1.90

-0.1 (-5.00%)

17:49
10/19/17
10/19
17:49
10/19/17
17:49
Hot Stocks
Titan Pharmaceuticals presents non-clinical data from liothyronine implant »

Titan Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSA

MSA Safety

$82.20

1.37 (1.69%)

17:46
10/19/17
10/19
17:46
10/19/17
17:46
Earnings
MSA Safety reports Q3 EPS 92c, consensus 80c »

Reports Q3 revenue $296M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

SKX

Skechers

$24.03

-1.06 (-4.22%)

, CAI

CAI International

$31.38

-0.05 (-0.16%)

17:41
10/19/17
10/19
17:41
10/19/17
17:41
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

SKX

Skechers

$24.03

-1.06 (-4.22%)

CAI

CAI International

$31.38

-0.05 (-0.16%)

PYPL

PayPal

$67.25

-0.01 (-0.01%)

MXIM

Maxim Integrated

$50.09

0.24 (0.48%)

IMDZ

Immune Design

$5.50

-1.05 (-16.03%)

NCR

NCR Corp.

$37.05

-0.26 (-0.70%)

TACO

Del Taco

$15.39

-0.01 (-0.06%)

ATHN

athenahealth

$116.41

-4.37 (-3.62%)

ISRG

Intuitive Surgical

$357.46

3.09 (0.87%)

ETFC

E-Trade

$43.69

-0.23 (-0.52%)

CELG

Celgene

$135.96

-1.21 (-0.88%)

PBMD

Prima BioMed

$2.36

-0.02 (-0.84%)

AAXN

Axon

$24.62

-0.37 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 21

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 29

    Nov

DGX

Quest Diagnostics

$93.23

1.18 (1.28%)

17:37
10/19/17
10/19
17:37
10/19/17
17:37
Hot Stocks
Quest Diagnostics acquires Cleveland HeartLab, terms not disclosed »

Advantage Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

AAXN

Axon

$24.62

-0.37 (-1.48%)

17:34
10/19/17
10/19
17:34
10/19/17
17:34
Hot Stocks
Axon says now aware of comment letter over SEC's review of 10-K, 10-Q »

Axon Enterprise said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMX

BioPharmX

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on BioPharmX »

BioPharmX files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBVX

MabVax Therapeutics

$0.74

0.0248 (3.47%)

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on MabVax Therapeutics »

MabVax Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBKC

Iberiabank

$80.15

0.05 (0.06%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Earnings
Iberiabank reports Q3 non-GAAP EPS $1.00, consensus $1.16 »

Reports Q3 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 15

    Nov

  • 28

    Nov

DRRX

Durect

$1.97

0.03 (1.55%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Hot Stocks
Breaking Hot Stocks news story on Durect »

Durect trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCP

Quality Care Properties

$16.26

0.07 (0.43%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Quality Care Properties provides update on HCR ManorCare »

Quality Care Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTR

Frontier Communications

$11.48

0.02 (0.17%)

, CHH

Choice Hotels

$68.45

0.25 (0.37%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Frontier Communications named a Qualified Vendor with Choice Hotels Internationa »

Frontier Communications…

FTR

Frontier Communications

$11.48

0.02 (0.17%)

CHH

Choice Hotels

$68.45

0.25 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 08

    Nov

DRIO

DarioHealth

$1.98

-0.2 (-9.17%)

17:16
10/19/17
10/19
17:16
10/19/17
17:16
Syndicate
Breaking Syndicate news story on DarioHealth  »

DarioHealth files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUBI

Customers Bancorp

$33.16

0.46 (1.41%)

17:11
10/19/17
10/19
17:11
10/19/17
17:11
Hot Stocks
Customers Bancorp to spin off BankMobile business »

Customers Bancorp plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 15

    Nov

MVC

MVC Capital

$10.40

0.08 (0.78%)

17:07
10/19/17
10/19
17:07
10/19/17
17:07
Hot Stocks
MVC Capital: Glass Lewis, Egan-Jones against proposal to cease new investments »

MVC Capital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

CELG

Celgene

$135.96

-1.21 (-0.88%)

17:05
10/19/17
10/19
17:05
10/19/17
17:05
Hot Stocks
Breaking Hot Stocks news story on Celgene »

Celgene down 6.6% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.